Public Health
11 articles on Public Health, written by Shotlee and medically reviewed for clinical accuracy.
Michelle Obama's Weight: Addressing Speculation and GLP-1 Rumors
Recent public appearances by Michelle Obama have sparked widespread discussion about her appearance and weight. This article delves into the speculation, explores the role of GLP-1 medications in weight management, and discusses the broader implications of public observation on health and wellness.
6 min read
Military's $700M GLP-1 Spending: Weight Loss Solutions or Taxpayer Burden?
The U.S. military has spent nearly $726 million on GLP-1 medications since 2021. This article delves into the controversy surrounding this expenditure, examining the obesity crisis within the armed forces and the debate over these weight-loss drugs.
7 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
India's Cheap GLP-1 Generics Risk Nutrition Gaps Amid Supplement Crisis
India's GLP-1 market surges with over 50 cheap generics from firms like Dr. Reddy's and Sun Pharma, priced as low as US$14/month post-patent expiry. Yet experts flag nutrition risks as appetite suppression drives reliance on substandard supplements failing label claims by 20-40%. Discover the quality crisis threatening diabetic and obese populations.
8 min read
RFK Jr.'s Peptide Push: Risks of Bypassing FDA Trials
Robert F. Kennedy Jr., US health secretary nominee, wants to open sales of restricted injectable peptides, fitting his Make America Healthy Again agenda. While some peptides show promise, the FDA halted 17 in 2023 due to safety risks—without trials, anecdote isn't evidence. This editorial warns against sidelining regulation for wellness hucksters.
4 min read
India's 2026 Healthcare Plan: Prioritizing Drug Quality, Innovation, TB, and Obesity | Mint
India's healthcare roadmap for 2026 prioritizes enhancing drug quality, expanding digital health services, and addressing critical public health issues such as tuberculosis and obesity. The government aims to transform India into a global life sciences hub by focusing on innovation and stringent quality standards.
5 min read
WHO Issues New Advice on GLP-1 Weight Loss Medications: Key Points
The World Health Organization (WHO) has provided new guidance on using GLP-1 drugs like Ozempic and Wegovy for obesity. The recommendations include considerations for adults and highlight the importance of lifestyle changes alongside medication.
2 min read
Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog
The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.
1 min read
Counterfeit Ozempic and Zepbound: Popularity Soars Despite Health Dangers
The popularity of weight loss medications, boosted by celebrity endorsements, has led to a surge in demand and a corresponding increase in counterfeit products. These fake drugs pose significant health risks, highlighting the need for caution and medical oversight.
5 min read
America's Most Obese States Unveiled: How Ozempic is Reshaping the Landscape
A recent report highlights the states with the highest obesity rates and analyzes the increasing use of GLP-1 medications such as Ozempic. The data reveals regional trends and potential impacts on public health, with higher usage in the South, Midwest, and Appalachia.
3 min read
Obesity Crisis in America Meets Ozempic Boom: Data Shows GLP-1 Hotspots
A recent report highlights the increasing use of GLP-1 medications like Ozempic and Mounjaro across the United States, with some states showing greater adoption than others. The data suggests a correlation between obesity rates and GLP-1 prescription rates, particularly in the South and Midwest.
3 min read